2017—2021年深圳市HPV疫苗AEFI发生情况分析  

Analysis of Adverse Events Following Immunization of Human Papillomavirus Vaccine in Shenzhen City, from 2017 to 2021

作　　者：张艳炜[1] 王苑玲[1] 黄芳[1] 谢旭[1] ZHANG Yanwei;WANG Yuanling;HUANG Fang;XIE Xu(Shenzhen Center for Disease Control and Prevention,Shenzhen,Guangdong 518055,China)

机构地区：[1]深圳市疾病预防控制中心,广东深圳518055

出　　处：《中国公共卫生管理》2023年第6期822-825,共4页Chinese Journal of Public Health Management

基　　金：深圳市医学重点学科公共卫生重点专科项目(SZXK064)。

摘　　要：目的分析深圳市2017—2021年进口人乳头瘤病毒(Human Papillomavirus,HPV)疫苗疑似预防接种异常反应(Adverse Events Following Immunization,AEFI)发生情况及临床表现。方法通过深圳市免疫规划信息管理系统和中国AEFI监测信息管理系统,收集2017—2021年深圳市进口HPV疫苗接种数量信息和AEFI报告数据。结果深圳市2017—2021年进口HPV疫苗AEFI发生率为10.88/10万,其中HPV2价、4价、9价疫苗AEFI发生率分别为17.01/10万、9.35/10万和11.68/10万;一般反应发生率为6.05/10万,异常反应发生率为2.84/10万,严重异常反应报告发生率为0.12/10万。结论深圳市进口HPV疫苗AEFI监测系统敏感度较好,报告发生率在预期范围内,严重异常反应罕见。Objective To analyze the incidence of Adverse Events Following Immunization(AEFI) with Human Papillomavirus(HPV) vaccine and the distribution characteristics of clinical symptoms in Shenzhen City from 2017 to2021. Methods Collecting the information of imported HPV vaccination and AEFI data from 2017 to 2021 in Shenzhen City through Shenzhen Immunization Program Information System and the China AEFI Surveillance Information Management System. Results The Overall AEFI incidence of imported HPV vaccines was 10.88 per 100 000 doses during 2017 to 2021, in Shenzhen. Incidence for HPV2, HPV4 and HPV9 were 17.01 per 100 000 doses, 9.35 per 100000 doses and 11.68 per 100 000 doses, respectively. Incidence of common adverse reactions and rare adverse reactions were 6.05 per 100 000 doses and 2.84 per 100 000 doses, respectively. The incidence of serious adverse reaction report was 0.12 per 100 000 doses. Conclusion The AEFI surveillance system of HPV vaccine in Shenzhen has good sensitivity, and the reported incidence is within the expected range, and serious AEFI are rare.

关 键 词：人乳头瘤病毒疫苗 疑似预防接种异常反应 监测 

分 类 号：R186[医药卫生—流行病学]